Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227290 · ClinicalTrials.gov registry record · Phase 4
Pediatric Subjects With Tinea Corporis
A Phase 4 study of Tinea Corporis, sponsored by Merz North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 230
- Enrollment target
- 19
- Study locations
NCT02227290: Completed Phase 4 study of Tinea Corporis, sponsored by Merz North America.
NCT02227290 is a Phase 4 study of Tinea Corporis that has completed, run by Merz North America. The registered enrollment target is 230 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02227290, a Phase 4 study of Tinea Corporis, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 230 participants
- Enrollment target
- 19
- Study locations
Study Summary
The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured.
Primary Outcome
Complete cure defined by negative KOH result and negative dermatophyte culture
Conditions Studied
Interventions
- DRUG Naftin Cream
- DRUG Placebo Cream
Study Locations (19)
Other
- Merz Investigative Site#180002 - San Cristóbal
- Merz Investigative Site# 180001 - Santo Domingo
- Merz Investigative Site#504001 - San Pedro Sula
- Merz Investigative Site#507001 - Panama City
- Merz Investigative Site#001279 - Cidra
California
- Investigative Site# 0010320 - Encino
- Merz Investigative Site#001313 - Fremont
- Merz Investigative Site#001301 - San Diego
Florida
- Merz Investigative Site#001312 - Miami
- Merz Investigative Site#001311 - Miami
- Merz Investigative Site #001310 - Miramar
North Carolina
- Merz Investigative Site#001126 - Raleigh
- Merz Investigative Site#001293 - Winston-Salem
Arizona
- Merz Investigative Site#001316 - Tucson
Missouri
- Merz Investigative Site#001307 - Saint Joseph
Nebraska
- Merz Investigative Site#001309 - Omaha
Nevada
- Merz Investigative Site#001314 - Henderson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
What the finished NCT02227290 record still lists
NCT02227290 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Tinea Corporis appearing as the primary indexed condition, and to 2 interventions - of which Naftin Cream is the first listed.
NCT02227290 lists 19 locations in 10 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02227290 about?
NCT02227290 is a clinical study titled "Pediatric Subjects With Tinea Corporis". The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured.
What is the current status of trial NCT02227290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 230 participants. The study started on 2014-08. Estimated completion is 2015-12.
What conditions does trial NCT02227290 study?
This clinical trial studies the following conditions: Tinea Corporis.
What interventions are being tested in trial NCT02227290?
The interventions under investigation include: Naftin Cream (DRUG), Placebo Cream (DRUG).
Who is sponsoring clinical trial NCT02227290?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02227290 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Corporis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02227290's enrollment target sits among peer trials
230 371st of 2000 higher than 1,628 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia